NCT03247790View on ClinicalTrials.gov

A Study of Lasmiditan in Participants With Migraine

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

January 15, 2018

Study Completion Date

January 15, 2018

Conditions
Migraine Disorders
Interventions
DRUG

Lasmiditan

Administered orally

Trial Locations (3)

33012

AGA Clinical Trials, Hialeah

33634

Meridien Research Inc., Tampa

92120

eStudySite, San Diego

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03247790 - A Study of Lasmiditan in Participants With Migraine | Biotech Hunter | Biotech Hunter